Wednesday, July 11, 2012

Surefire Techniques for Biospecimen Tracking and Management

You can’t get anything of value from your biospecimens until you have the skills to accurately track and monitor them. Are you completely certain of the age, origin, disease state, informed consent status, and extent of any prior research on every single one of your samples? And do you have the technical capacity to find them at critical moments?

This year’s Biorepositories conference offers in-depth training on the specimen tracking and monitoring techniques on which your entire research pipeline depends.

Don’t miss these exclusive case studies:
  • • PFIZER demonstrates a Framework for Evaluating and Improving your Systems and Repositories to Get the Most from your Data
  • • IPSEN analyzes how to Scale the Bioinformatics and IT Needs for Biospecimen Management among Small to Mid-Size Pharma & Biotech Companies
  • • INFINITY PHARMACEUTICALS details the Proactive Design of Informed Consent Compliance Methods that Work for Your Institution
  • • EMORY UNIVERSITY pinpoints methods for Establishing Clear and Consistent Terminology to Identify and Track Banked Specimens
Now in its 5th year, the Biorepositories conference is the only event in the United States that focuses entirely on the biospecimen acquisition, management, and preservation challenges of the pharmaceutical and biotech industries, as well as the critical areas where industry and academia can share their specimens and knowledge to accelerate drug breakthroughs.

For more information the Biorepositories Event, visit the homepage.

For an in-depth look at Biorepositories and the other four events of the Clinical Business Expo, download the brochure.

Biorepositories & Sample Management and the Clinical Business Expo will take place September 19-20, 2012 with a pre-conference day September 18. As a reader of this blog, when you register to join us today and mention code XP1725BLOG, you’ll save 15% off the standard rate! If you have any questions, feel free to email Jennifer Pereira.




No comments: